Education
About Us
Working with TipRanks
Follow Us
BioAge Labs, Inc. (BIOA)
NASDAQ:BIOA
BIOA Stock Chart & Stats
$13.39
-$0.31(-5.78%)
At close: 4:00 PM EST
$13.39
-$0.31(-5.78%)
Day’s Range― - ―
52-Week Range$2.88 - $13.10
Previous CloseN/A
Volume146.35K
Average Volume (3M)196.83K
Market Cap
$480.10M
Enterprise Value-$140.49M
Total Cash (Recent Filing)$285.78M
Total Debt (Recent Filing)$7.13M
Price to Earnings (P/E)―
Beta1.55
Next Earnings
Mar 19, 2026EPS Estimate
-0.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.56
Shares Outstanding35,855,038
10 Day Avg. Volume197,907
30 Day Avg. Volume196,830
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.19
Price to Sales (P/S)0.00
P/FCF Ratio-1.20
Enterprise Value/Market Cap-0.29
Enterprise Value/Revenue-23.74
Enterprise Value/Gross Profit-23.74
Enterprise Value/Ebitda1.88
Forecast
1Y Price Target
$13.50Price Target Upside0.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DataInitial clinical data for BGE-102 highlights robust biomarker reductions, suggesting potential to reduce cardiovascular risk.
Investor InterestRecent investor resurgence in the NLRP3 pathway may reframe NLRP3 inhibitors as promising therapeutic options.
Safety And ToleranceTreatment was well tolerated at all dose levels in both the SAD and MAD cohorts.
Bears Say
Financial PerformanceBioAge reported a net loss of $20.2 million for the third quarter, which was worse than the estimated net loss.
Operating ExpensesHigher-than-expected R&D expenses primarily drove the difference between estimated and reported operating results.
BioAge Labs, Inc. News
BIOA FAQ
What was BioAge Labs, Inc.’s price range in the past 12 months?
BioAge Labs, Inc. lowest stock price was $2.88 and its highest was $13.10 in the past 12 months.
What is BioAge Labs, Inc.’s market cap?
BioAge Labs, Inc.’s market cap is $480.10M.
When is BioAge Labs, Inc.’s upcoming earnings report date?
BioAge Labs, Inc.’s upcoming earnings report date is Mar 19, 2026 which is in 86 days.
How were BioAge Labs, Inc.’s earnings last quarter?
BioAge Labs, Inc. released its earnings results on Nov 06, 2025. The company reported -$0.56 earnings per share for the quarter, beating the consensus estimate of -$0.584 by $0.024.
Is BioAge Labs, Inc. overvalued?
According to Wall Street analysts BioAge Labs, Inc.’s price is currently Undervalued.
Does BioAge Labs, Inc. pay dividends?
BioAge Labs, Inc. does not currently pay dividends.
What is BioAge Labs, Inc.’s EPS estimate?
BioAge Labs, Inc.’s EPS estimate is -0.77.
How many shares outstanding does BioAge Labs, Inc. have?
BioAge Labs, Inc. has 35,855,038 shares outstanding.
What happened to BioAge Labs, Inc.’s price movement after its last earnings report?
BioAge Labs, Inc. reported an EPS of -$0.56 in its last earnings report, beating expectations of -$0.584. Following the earnings report the stock price went down -2.811%.
Which hedge fund is a major shareholder of BioAge Labs, Inc.?
Currently, no hedge funds are holding shares in BIOA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioAge Labs, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.50 (0.82% Upside)
$13.50 (0.82% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-77.46%
12-Months-Change
Fundamentals
Return on Equity
-25.64%
Trailing 12-Months
Asset Growth
95.95%
Trailing 12-Months
Company Description
BioAge Labs, Inc.
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.
BIOA Stock 12 Month Forecast
Average Price Target
$13.50
▲(0.82% Upside)
Technical Analysis
Ironwood Pharma
―
Lifecore Biomedical
―
China SXT Pharmaceuticals
―
Journey Medical Corp
―
Incannex Healthcare Limited Sponsored ADR
―
Ownership Overview
9.02% Insiders
5.98% Mutual Funds
42.34% Other Institutional Investors
35.03% Public Companies and
Individual Investors